Objective:
To review the latest data on treatments for neovascular age-related macular degeneration (AMD) and discuss new investigational agents.
Key Findings:
- Vabysmo and Eylea HD show maintained durability and stable best-corrected visual acuity (BCVA) over extended periods.
- Susvimo demonstrates maintained BCVA and central subfield thickness (CST) reductions with great durability.
- New anti-VEGF TH-103 shows enhanced activity and durability due to improved binding properties.
Interpretation:
The treatment landscape for wet AMD is evolving with promising long-term data supporting existing therapies and the introduction of innovative treatment options.
Limitations:
- The studies reviewed may have limitations in generalizability to broader populations.
- Long-term safety and efficacy of new investigational agents are still under evaluation.
Conclusion:
The advancements in treatment options for wet AMD provide hope for improved patient outcomes and highlight the importance of ongoing research.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
